Maha records a 9% death rate on those who have mukormycosis

Pune: Maharashtra has recorded a 9% death rate among patients diagnosed with covid-related mucormosis (cam) over the past three months.
The death rate is far below the range of 30-50% seen in mukormycosis patients before the pandemic.
Of a total of 7,359 cam patients in Maharashtra until June 14, 653 had given up.
Of the five worst state districts, Pune has recorded a 12% death rate and was attended by Nashik (10%), Mumbai (9%), Nagpur (8%) and Aurangabad (7%).
Experts connect the state mortality rate for rapid efforts by doctors and the use of available anti-mukormycosis drugs such as Posaconazole and Isovuconazole amid a lack of major drugs such as Amphotericin B.
But health activists say they are afraid of many patients who cannot continue home care Expensive pain and death at home may not be reported.
Medical experts also said it was too early to calculate the mortality rate of covid mucormycosis.
Thane-based ENT surgeons and members of the State Task Force in Covid-related Mukormycosis, Ashesh Bhumkar, said, “Covid-related mukormycosis is very different from the mucatorcosis of the pre-covid era.” He said, “In post-covid musicycosis, immunocompetent patients and fighting fungi are very hard.
Some patients are also younger and healed better.
In addition, the diagnosis was made very early and the treatment began quickly.” He added that investigations like MRI scanning Now it’s better, optimal surgical treatment and other glucose and electrolyte controls have been set.
“All of these factors are responsible for low mortality rates at this time,” said Bhumkar.
Pune-Based Ent Surgeon Pune Rajeev Yande said, “The current mortality rate is far below the expected mortality rate of mucorikosis.
This surprising statistical facts can be associated with a quick and timely multi-disciplinary response from specialists – from a piece of surgery, The affected network to manage anti-fungal drugs.
“Yande said the surgeon, enriched with experience, capable of surgery devoting disease, making the network responsive to drugs.
“Steroid treatment which is limited only for patients shown can also contribute to reducing the mortality rate,” he said.
Others agree is still too early to comment on the level of death or recovery.
“Mucormycosis kills slowly, especially with intra-cranial deployment.
We haven’t seen this in a significant amount,” said Tht Surgeon Samir Joshi.
Joshi said, “Some patients die from sepsis, long-term lung complications and ketoasidosis, serious diabetes complications.
Strictly, they are not because of mukormycosis.”